Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVF (oral fentanyl) for cancer breakthrough pain
jRCT2080220446Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer pain and breakthrough pain comparing OVF (fentanyl buccal) with Placebo buccal (2 arms).
02
Drugs
fentanyl
03
Conditions
cancer painbreakthrough pain
Beyond the preview
Go deeper on jRCT2080220446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220446.